Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications
{{output}}
Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as the primary therapy for initial CDI episodes and suggest alternative approaches fo... ...
